MIGRA-Cell Delivery Platform

About Migra-Therapeutics

MIGRA-Therapeutics is a private, preclinical-stage biotech focused on overcoming a major hurdle in cancer treatment: delivering therapeutics effectively into dense, resistant solid tumors. The company's platform utilizes hyaluronic acid nanoparticles and protease-enabled systems to create stroma-penetrating delivery vehicles for both chemotherapy drugs and therapeutic cells like CAR-Ts. With foundational support from NIH SBIR grants and strong academic ties, MIGRA is advancing its lead candidate, MIGRA-NP01, towards IND-enabling studies for pancreatic cancer while seeking partnerships to broaden the platform's application.

Therapeutic Areas